UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000029183
Receipt number R000033364
Scientific Title Potential roles of neurotransmitter receptors and mitochondria in the pathophysiology of autism spectrum disorder: A PET study
Date of disclosure of the study information 2017/11/15
Last modified on 2022/09/24 21:22:23

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Potential roles of neurotransmitter receptors and mitochondria in the pathophysiology of autism spectrum disorder: A PET study

Acronym

Neurotransmitter receptors and mitochondria
in autism spectrum disorder

Scientific Title

Potential roles of neurotransmitter receptors and mitochondria in the pathophysiology of autism spectrum disorder: A PET study

Scientific Title:Acronym

Neurotransmitter receptors and mitochondria
in autism spectrum disorder

Region

Japan


Condition

Condition

Autism spectrum disorder

Classification by specialty

Psychiatry

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

Autism spectrum disorder (ASD) is a highly prevalent neurodevelopmental disorder as high as 1%. No pharmacological treatment for its core symptoms has been established. Although mitochondria and neurotransmitters such as dopamine might play a role in the pathophysiology of ASD, previous studies have not fully elucidated it. Furthermore, a potential role of their interactions has not yet been tested.The current study will test the role of dopamine and mitochondria and their interactions in the pathophysiology of ASD by utilizing [11C]FLB457 and [18F]BCPP-EF PET.

Basic objectives2

Others

Basic objectives -Others

We will compare the binding potentials of [11C] FLB457 and standard uptake value ratio of [18F] BCPP-EF in ASD individuals with those in typically developped subjects.

Trial characteristics_1

Exploratory

Trial characteristics_2

Pragmatic

Developmental phase

Not applicable


Assessment

Primary outcomes

The binding potentials of [11C] FLB and standard uptake value ratio of [18F] BCPP-EF

Key secondary outcomes

Indices assessed with MRI Psychological tests : ADOS-2(Autism Diagnostic Observation Schedule Second Edition),ADI-R(Autism Diagnostic Interview-Revised),AQ(Autism-Spectrum Quotient),STAI(State-Trait Anxiety Inventory),SASS( Social Adaptation Self-evaluation Scale),CES-D(The Center for Epidemiologic Studies Depression Scale),CGI-S( Clinical Global Impressions-Severity of Illness scale),WAIS-3(Wechsler Adult Intelligence Scale third edition)
Labo date:lactate,pyruvate,ammoniaasparate aminotransferase,alanine aminotransferase,creatine kinase,
creatinine


Base

Study type

Interventional


Study design

Basic design

Single arm

Randomization

Non-randomized

Randomization unit


Blinding

Open -no one is blinded

Control

Uncontrolled

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

1

Purpose of intervention

Diagnosis

Type of intervention

Device,equipment

Interventions/Control_1

We use[11C]-FLB457 and [18F]BCPP-EF as radiotracer by administration intravenously

Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

18 years-old <=

Age-upper limit

60 years-old >

Gender

Male

Key inclusion criteria

Health control
-Without past or current history psychiatric illness

Illnesses groups
-Diagnosed as autism spectrum disorder on DSM-5
-Full IQ above 70
-Without nervous disease

Key exclusion criteria

-With current history of brain organic diseases

Target sample size

60


Research contact person

Name of lead principal investigator

1st name HIDENORI
Middle name
Last name YAMASUE

Organization

Hamamatsu University school of medicine

Division name

psychiatry

Zip code

431-3192

Address

1-20-1 Handayama, Higashi-ku, Hamamatsu, Shizuoka, Japan

TEL

053-435-2295

Email

yamasue@hama-med.ac.jp


Public contact

Name of contact person

1st name Kato
Middle name
Last name Yasuhiko

Organization

Hamamatsu University school of medicine

Division name

psychiatry

Zip code

4380085

Address

1-20-1 Handayama, Higashi-ku, Hamamatsu, Shizuoka, Japan

TEL

09061277594

Homepage URL


Email

katounagi.y@gmail.com


Sponsor or person

Institute

Hamamatsu University school of medicine

Institute

Department

Personal name



Funding Source

Organization

Japan Agency for Medical Research and Development

Organization

Division

Category of Funding Organization

Government offices of other countries

Nationality of Funding Organization



Other related organizations

Co-sponsor

Hamamatsu Photonics
Hamamatsu Medical Photonics Foundation

Name of secondary funder(s)



IRB Contact (For public release)

Organization

Hamamatsu University school of medicine

Address

1-20-1 Handayama, Higashi-ku, Hamamatsu, Shizuoka, Japan

Tel

053-435-2295

Email

rinri@hama-med.ac.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2017 Year 11 Month 15 Day


Related information

URL releasing protocol


Publication of results

Published


Result

URL related to results and publications


Number of participants that the trial has enrolled

47

Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2017 Year 10 Month 31 Day

Date of IRB

2017 Year 08 Month 10 Day

Anticipated trial start date

2017 Year 10 Month 31 Day

Last follow-up date

2022 Year 09 Month 30 Day

Date of closure to data entry

2022 Year 09 Month 30 Day

Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2017 Year 09 Month 19 Day

Last modified on

2022 Year 09 Month 24 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000033364


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name